Oxford BioMedica fills leadership vacancy
pharmafile | October 14, 2008 | News story | Research and Development, Sales and Marketing |Â Â biotechÂ
Oxford BioMedica has settled on a permanent chief executive, promoting John Dawson from his acting leadership position.
Chairman professor Alan Kingsman said Dawson's performance since joining the company two months ago had earned him the new role.
He added: "Since taking the role on an interim basis in August, John has demonstrated his strategic and leadership qualities. With his commitment to the company and successful track record of building biopharmaceutical companies, the Board concluded that John is the best candidate to take Oxford BioMedica through its next phase of growth."
Dawson succeeded Dr Mike McDonald, who stepped down from the lead role just one month after he was appointed.
The reason for McDonald's departure was not clear, but there were reported concerns over his recovery strategy for the company.
Its lead vaccine TroVax suffered a serious setback earlier this year when it failed a key trial in kidney cancer and, although half-year figures were relatively strong, the company's dwindling cash position requires it to prioritise resources.
New leader John Dawson has a background in mergers and acquisitions, and is said to be looking for new deals to boost the company pipeline. From 1996 to 2007, he held senior management positions in the European operations of Cephalon.
Commenting on his appointment, John Dawson said: "This is an exceptional company with an experienced management team, strong pipeline and leading technology. I look forward to the challenges ahead as we pursue our objective of becoming a highly-valued, profitable biopharmaceutical company."
Related Links:
Oxford BioMedica unsettled by chief executive's departure
Wednesday, September 10, 2008
Related Content
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
